EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection

Yuan Tian iD, Mingming Zhang iD, Syed Luqman Ali iD, Aigul Abduldayeva, Shuang Zhou iD, Yajing An iD, Yufeng Li iD, Ruizi Ni iD, Lingxia Zhang iD, Yanhua Liu iD, Weiguo Sun, Wenping Gong iD

Pathogens · 2026

DOI: 10.3390/pathogens15030297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2026. Verfasst von Yuan Tian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Tuberculosis, Chinese PLA General Hospital, Beijing 100091, China. Hauptthemen laut MEDLINE: Latent Tuberculosis, Epitopes, T-Lymphocyte, Tuberculosis Vaccines, Mycobacterium tuberculosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Latent tuberculosis infection (LTBI) is the principal reservoir for active tuberculosis, with >85% of cases attributable to reactivation. Bacillus Calmette-Guérin fails to block this transition, leaving a critical gap in prevention.

Methods

An immunoinformatics/reverse-vaccinology pipeline was applied to seven dormancy-related antigens retrieved from Mycobrowser. T-cell epitopes were predicted with NetMHCI/IIpan-4.1 and B-cell epitopes with ABCpred; antigenicity, allergenicity, and toxicity were evaluated with VaxiJen, AllerTOP, and ToxinPred. Secondary/tertiary structures were modeled with PSIPRED and AlphaFold-3; docking to Toll-like receptors (TLR) 2/4 and 100 ns molecular dynamics simulations assessed complex stability. Immune responses were simulated with C-ImmSim, and the mRNA sequence was human-codon-optimized using ExpOptimizer.

Results

The resulting construct, RP14914P, encodes 14 cytotoxic T lymphocyte, 9 helper T lymphocyte, and 14 B-cell epitopes within an 866-aa, 90.4 kDa polypeptide. Antigenicity score = 0.7797, immunogenicity score = 8.58629. and no toxicity or allergenicity was predicted. Physicochemical analysis: instability index = 28.65, and solubility = 0.513. Estimated population coverage is 82.35% and 99.67% for Human Leukocyte Antigen (HLA)-I and HLA-II globally. Docking energies: −1477.8 kcal/mol (TLR2) and −1480.1 kcal/mol (TLR4). Molecular dynamics trajectories confirm stable binding. Immune simulation predicts potent activation of Natural Killer cells, macrophages, and dendritic cells, Th1 polarization, high interferon-γ/interleukin-2 secretion, and durable memory.

Conclusions

In silico analyses predict that RP14914P exhibits favorable immunogenicity, safety, and broad population coverage, suggesting its potential as a promising mRNA vaccine candidate to prevent LTBI reactivation. However, these computational predictions require thorough experimental validation to confirm the vaccine’s immunogenicity and protective efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Latent TuberculosisEpitopes, T-LymphocyteTuberculosis VaccinesMycobacterium tuberculosisRNA, MessengerHumansImmunoinformaticsEpitopes, B-LymphocyteMolecular Docking SimulationReverse VaccinologyAntigens, BacterialVaccines, SyntheticMolecular Dynamics Simulation

Stichwörter der Autor:innen

immune simulationimmunoinformaticsmolecular dockingmulti-epitope vaccinereverse vaccinologyvaccine design

Substanzen

Epitopes, T-LymphocyteTuberculosis VaccinesEpitopes, B-LymphocyteRNA, MessengerAntigens, BacterialVaccines, Synthetic

Autor:innen und Institutionen

  • Senior Department of Tuberculosis, Chinese PLA General Hospital, Beijing 100091, China.
  • Graduate School, Hebei North University, Zhangjiakou 075000, China.
  • Department of Biochemistry, Abdul Wali Khan University, Mardan 23200, Pakistan.
  • Department of Research Institute of Preventive Medicine Named Academician E. Dalenov, Astana Medical University, Astana 010000, Kazakhstan.
  • Department of Geriatrics, The Eighth Medical Center of PLA General Hospital, Beijing 100091, China.

ORCID-Profile: Yuan Tian, Mingming Zhang, Syed Luqman Ali, Shuang Zhou, Yajing An, Yufeng Li, Ruizi Ni, Lingxia Zhang, Yanhua Liu, Wenping Gong

Zitieren

APA

Tian, Y., Zhang, M., Ali, S. L., Abduldayeva, A., Zhou, S., An, Y., Li, Y., Ni, R., Zhang, L., Liu, Y., Sun, W., & Gong, W. (2026). Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection. Pathogens. https://doi.org/10.3390/pathogens15030297

Vancouver

Tian Y, Zhang M, Ali SL, Abduldayeva A, Zhou S, An Y, et al. Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection. Pathogens. 2026. doi:10.3390/pathogens15030297

BibTeX
@article{Tian2026,
  author = {Tian, Yuan and Zhang, Mingming and Ali, Syed Luqman and Abduldayeva, Aigul and Zhou, Shuang and An, Yajing and Li, Yufeng and Ni, Ruizi and Zhang, Lingxia and Liu, Yanhua and Sun, Weiguo and Gong, Wenping},
  title = {Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection},
  journal = {Pathogens},
  year = {2026},
  doi = {10.3390/pathogens15030297}
}
Kostenlos starten →